miR-181a Upregulation Promotes Radioresistance of Nasopharyngeal Carcinoma by Targeting RKIP

References

• Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-031178151
   PubMed Web of Science ®Google Scholar
• Leong YH, Soon YY, Lee KM, et al. Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: a meta-analysis. Head Neck. 2018;40(3):622–631. doi:10.1002/hed.v40.329130584
   PubMed Web of Science ®Google Scholar
• Lam WKJ, Chan JYK. Recent advances in the management of nasopharyngeal carcinoma. F1000Res. 2018;7. doi:10.12688/f1000research.15066.1
   Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203. doi:10.1038/nrd.2016.24628209991
   PubMed Web of Science ®Google Scholar
• Ahmad P, Sana J, Slavik M, et al. MicroRNAs involvement in radioresistance of head and neck cancer. Dis Markers. 2017;2017:8245345. doi:10.1155/2017/824534528325958
   PubMed Web of Science ®Google Scholar
• Fanale D, Castiglia M, Bazan V, Russo A. Involvement of non-coding RNAs in chemo- and radioresistance of colorectal cancer. Adv Exp Med Biol. 2016;937:207–228.27573902
   PubMed Web of Science ®Google Scholar
• Li XH, Qu JQ, Yi H, et al. Integrated analysis of differential miRNA and mRNA expression profiles in human radioresistant and radiosensitive nasopharyngeal carcinoma cells. PLoS One. 2014;9(1):e87767. doi:10.1371/journal.pone.008776724498188
   PubMed Web of Science ®Google Scholar
• Qu JQ, Yi HM, Ye X, et al. MiR-23a sensitizes nasopharyngeal carcinoma to irradiation by targeting IL-8/Stat3 pathway. Oncotarget. 2015;6(29):28341. doi:10.18632/oncotarget.511726314966
   PubMed Web of Science ®Google Scholar
• Qu JQ, Yi HM, Ye X, et al. MiRNA-203 reduces nasopharyngeal carcinoma radioresistance by targeting IL8/AKT signaling. Mol Cancer Ther. 2015;14(11):2653–2664. doi:10.1158/1535-7163.MCT-15-046126304234
   PubMed Web of Science ®Google Scholar
• Zheng Z, Qu JQ, Yi HM, et al. MiR-125b regulates proliferation and apoptosis of nasopharyngeal carcinoma by targeting A20/NF-kappaB signaling pathway. Cell Death Dis. 2017;8(6):e2855. doi:10.1038/cddis.2017.21128569771
   PubMedGoogle Scholar
• Zaravinos A, Bonavida B, Chatzaki E, Baritaki S. RKIP: a key regulator in tumor metastasis initiation and resistance to apoptosis: therapeutic targeting and impact. Cancers (Basel). 2018;10(9):287. doi:10.3390/cancers10090287
   PubMed Web of Science ®Google Scholar
• Farooqi AA, Li Y, Sarkar FH. The biological complexity of RKIP signaling in human cancers. Exp Mol Med. 2015;47:e185. doi:10.1038/emm.2015.7026403261
   PubMed Web of Science ®Google Scholar
• Raquel-Cunha A, Cardoso-Carneiro D, Reis RM, Martinho O. Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signaling. Cells. 2019;8(5):442. doi:10.3390/cells8050442
   PubMed Web of Science ®Google Scholar
• Guo W, Dong Z, Guo Y, et al. Aberrant methylation and loss expression of RKIP is associated with tumor progression and poor prognosis in gastric cardia adenocarcinoma. Clin Exp Metastasis. 2013;30(3):265–275. doi:10.1007/s10585-012-9533-x22983529
   PubMed Web of Science ®Google Scholar
• Nieh S, Jao SW, Yang CY, et al. Regulation of tumor progression via the snail-RKIP signaling pathway by nicotine exposure in head and neck squamous cell carcinoma. Head Neck. 2015;37(12):1712–1721. doi:10.1002/hed.2382024986226
   PubMed Web of Science ®Google Scholar
• Du Y, Liu XH, Zhu HC, et al. MiR-543 promotes proliferation and epithelial-mesenchymal transition in prostate cancer via targeting RKIP. Cell Physiol Biochem. 2017;41(3):1135–1146. doi:10.1159/00046412028245474
   PubMedGoogle Scholar
• Yuan L, Yi HM, Yi H, et al. Reduced RKIP enhances nasopharyngeal carcinoma radioresistance by increasing ERK and AKT activity. Oncotarget. 2016;7(10):11463. doi:10.18632/oncotarget.720126862850
   PubMedGoogle Scholar
• Feng XP, Yi H, Li MY, et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res. 2010;70(9):3450–3462. doi:10.1158/0008-5472.CAN-09-409920406978
   PubMed Web of Science ®Google Scholar
• Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, Martin OA. Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett. 2012;327(1–2):123–133. doi:10.1016/j.canlet.2011.12.02522198208
   PubMed Web of Science ®Google Scholar
• Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Database issue):D92–D97. doi:10.1093/nar/gkt124824297251
   PubMed Web of Science ®Google Scholar
• Malla B, Zaugg K, Vassella E, Aebersold DM, Dal Pra A. Exosomes and exosomal MicroRNAs in prostate cancer radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(5):982–995. doi:10.1016/j.ijrobp.2017.03.03128721912
   PubMed Web of Science ®Google Scholar
• Malik A, Sultana M, Qazi A, et al. Role of natural radiosensitizers and cancer cell radioresistance: an update. Anal Cell Pathol (Amst). 2016;2016:6146595.26998418
   PubMedGoogle Scholar
• Huang T, Yin L, Wu J, et al. MicroRNA-19b-3p regulates nasopharyngeal carcinoma radiosensitivity by targeting TNFAIP3/NF-kappaB axis. J Exp Clin Cancer Res. 2016;35(1):188. doi:10.1186/s13046-016-0465-127919278
   PubMedGoogle Scholar
• Wang S, Zhang R, Claret FX, Yang H. Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. Mol Cancer Ther. 2014;13(12):3163–3174. doi:10.1158/1535-7163.MCT-14-031725319395
   PubMed Web of Science ®Google Scholar
• Wang S, Pan Y, Zhang R, et al. Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3ʹUTR and 5ʹUTR of Jab1/CSN5. Oncogene. 2016;35(47):6096. doi:10.1038/onc.2016.14727157611
   PubMed Web of Science ®Google Scholar
• Li G, Wang Y, Liu Y, et al. miR-185-3p regulates nasopharyngeal carcinoma radioresistance by targeting WNT2B in vitro. Cancer Sci. 2014;105(12):1560–1568. doi:10.1111/cas.2014.105.issue-1225297925
   PubMed Web of Science ®Google Scholar
• Li G, Liu Y, Su Z, et al. MicroRNA-324-3p regulates nasopharyngeal carcinoma radioresistance by directly targeting WNT2B. Eur J Cancer. 2013;49(11):2596–2607. doi:10.1016/j.ejca.2013.03.00123583221
   PubMed Web of Science ®Google Scholar
• Zhang X, Li X, Tan F, Yu N, Pei H. STAT1 inhibits MiR-181a expression to suppress colorectal cancer cell proliferation through PTEN/Akt. J Cell Biochem. 2017;118(10):3435–3443. doi:10.1002/jcb.v118.1028322462
   PubMed Web of Science ®Google Scholar
• Yang M, Zhai X, Ge T, Yang C, Lou G. miR-181a-5p promotes proliferation and invasion and inhibits apoptosis of cervical cancer cells via regulating Inositol Polyphosphate-5-Phosphatase A (INPP5A). Oncol Res. 2018;26(5):703–712. doi:10.3727/096504017X1498256937751128653606
   PubMed Web of Science ®Google Scholar
• Mi Y, Zhang D, Jiang W, et al. miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation. Cancer Lett. 2017;389:11–22. doi:10.1016/j.canlet.2016.12.03328043911
   PubMed Web of Science ®Google Scholar
• Lei Z, Ma X, Li H, et al. Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis. Urol Oncol. 2018;36(3):93e23–93e37. doi:10.1016/j.urolonc.2017.09.019
   Web of Science ®Google Scholar
• Le F, Luo P, Yang QO, Zhong XM. MiR-181a promotes growth of thyroid cancer cells by targeting tumor suppressor RB1. Eur Rev Med Pharmacol Sci. 2017;21(24):5638–5647. doi:10.26355/eurrev_201712_1400729271997
   PubMed Web of Science ®Google Scholar
• Shi Q, Zhou Z, Ye N, et al. MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1. Cancer Biomark. 2017;20(4):539–546. doi:10.3233/CBM-17035028946554
   PubMed Web of Science ®Google Scholar
• Han P, Li JW, Zhang BM, et al. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/beta-catenin signaling. Mol Cancer. 2017;16(1):9. doi:10.1186/s12943-017-0583-128086904
   PubMed Web of Science ®Google Scholar
• Neu J, Dziunycz PJ, Dzung A, et al. miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS. PLoS One. 2017;12(9):e0185028. doi:10.1371/journal.pone.018502828931048
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang W, Ji W. miR-181a targets GATA6 to inhibit the progression of human laryngeal squamous cell carcinoma. Future Oncol. 2018;14(17):1741–1753. doi:10.2217/fon-2018-006429517349
   PubMed Web of Science ®Google Scholar
• Ke G, Liang L, Yang JM, et al. MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. Oncogene. 2013;32(25):3019–3027. doi:10.1038/onc.2012.32322847611
   PubMed Web of Science ®Google Scholar
• Chen G, Zhu W, Shi D, et al. MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep. 2010;23(4):997–1003. doi:10.3892/or_0000072520204284
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang W, Hao S. LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis. Cell Cycle. 2017;16(8):795–801. doi:10.1080/15384101.2017.130133428358263
   PubMed Web of Science ®Google Scholar
• Woods Ignatoski KM, Grewal NK, Markwart SM, et al. Loss of raf kinase inhibitory protein induces radioresistance in prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(1):153–160. doi:10.1016/j.ijrobp.2008.04.07218722266
   PubMed Web of Science ®Google Scholar
• Xie SY, Li G, Han C, Yu YY, Li N. RKIP reduction enhances radioresistance by activating the Shh signaling pathway in non-small-cell lung cancer. Onco Targets Ther. 2017;10:5605. doi:10.2147/OTT.S14920029200875
   PubMed Web of Science ®Google Scholar